These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 17505821)

  • 1. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.
    Donald PR; Parkin DP; Seifart HI; Schaaf HS; van Helden PD; Werely CJ; Sirgel FA; Venter A; Maritz JS
    Eur J Clin Pharmacol; 2007 Jul; 63(7):633-9. PubMed ID: 17505821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid.
    Donald PR; Sirgel FA; Venter A; Parkin DP; Seifart HI; van de Wal BW; Werely C; van Helden PD; Maritz JS
    Clin Infect Dis; 2004 Nov; 39(10):1425-30. PubMed ID: 15546075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China.
    Jing W; Zong Z; Tang B; Wang J; Zhang T; Wen S; Xue Y; Chu N; Zhao W; Huang H
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis.
    Schaaf HS; Parkin DP; Seifart HI; Werely CJ; Hesseling PB; van Helden PD; Maritz JS; Donald PR
    Arch Dis Child; 2005 Jun; 90(6):614-8. PubMed ID: 15908628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients.
    Zabost A; Brzezińska S; Kozińska M; Błachnio M; Jagodziński J; Zwolska Z; Augustynowicz-Kopeć E
    Biomed Res Int; 2013; 2013():853602. PubMed ID: 24383060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.
    Cordes H; Thiel C; Aschmann HE; Baier V; Blank LM; Kuepfer L
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6134-45. PubMed ID: 27480867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.
    Jung JA; Kim TE; Lee H; Jeong BH; Park HY; Jeon K; Kwon OJ; Ko JW; Choi R; Woo HI; Koh WJ; Lee SY
    Drug Des Devel Ther; 2015; 9():5433-8. PubMed ID: 26491254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Rapid Pharmacogenomic Assay to Detect
    Verma R; Patil S; Zhang N; Moreira FMF; Vitorio MT; Santos ADS; Wallace E; Gnanashanmugam D; Persing DH; Savic RM; Croda J; Andrews JR
    Am J Respir Crit Care Med; 2021 Dec; 204(11):1317-1326. PubMed ID: 34375564
    [No Abstract]   [Full Text] [Related]  

  • 9. Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2.
    Kubota R; Ohno M; Hasunuma T; Iijima H; Azuma J
    Eur J Clin Pharmacol; 2007 Oct; 63(10):927-33. PubMed ID: 17665185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of isoniazid in low-birth-weight and premature infants.
    Bekker A; Schaaf HS; Seifart HI; Draper HR; Werely CJ; Cotton MF; Hesseling AC
    Antimicrob Agents Chemother; 2014; 58(4):2229-34. PubMed ID: 24492365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis.
    Cho YS; Jang TW; Kim HJ; Oh JY; Lee HK; Park HK; Ghim JL; Long NP; Park Y; Choi YK; Phuong NTT; Shin JG;
    J Clin Pharmacol; 2021 Dec; 61(12):1567-1578. PubMed ID: 34157153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis.
    Donald PR; Sirgel FA; Botha FJ; Seifart HI; Parkin DP; Vandenplas ML; Van de Wal BW; Maritz JS; Mitchison DA
    Am J Respir Crit Care Med; 1997 Sep; 156(3 Pt 1):895-900. PubMed ID: 9310010
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Mthiyane T; Millard J; Adamson J; Balakrishna Y; Connolly C; Owen A; Rustomjee R; Dheda K; McIlleron H; Pym AS
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of N-acetyltransferase 2 genotype and acetylation status with plasma isoniazid concentration and its metabolic ratio in ethiopian tuberculosis patients.
    Sileshi T; Telele NF; Burkley V; Makonnen E; Aklillu E
    Sci Rep; 2023 Jul; 13(1):11438. PubMed ID: 37454203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.
    Azuma J; Ohno M; Kubota R; Yokota S; Nagai T; Tsuyuguchi K; Okuda Y; Takashima T; Kamimura S; Fujio Y; Kawase I;
    Eur J Clin Pharmacol; 2013 May; 69(5):1091-101. PubMed ID: 23150149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a limited sampling strategy for the estimation of isoniazid exposure considering N-acetyltransferase 2 genotypes in Korean patients with tuberculosis.
    Lee J; Choi G; Yang S; Ha JE; Kim ES; Park JS; Lee K; Song J; Lee JH; Lee JI
    Tuberculosis (Edinb); 2021 Mar; 127():102052. PubMed ID: 33548864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age-distribution and genotype-phenotype correlation for N-acetyltransferase in Argentine children under isoniazid treatment.
    Keller GA; Fabian L; Gomez M; Gonzalez CD; Diez RA; Di Girolamo G
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):292-302. PubMed ID: 24447650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis.
    Parkin DP; Vandenplas S; Botha FJ; Vandenplas ML; Seifart HI; van Helden PD; van der Walt BJ; Donald PR; van Jaarsveld PP
    Am J Respir Crit Care Med; 1997 May; 155(5):1717-22. PubMed ID: 9154882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid.
    Balhara A; Singh S
    Pharm Res; 2021 Sep; 38(9):1485-1496. PubMed ID: 34518943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Type of isoniazid (INH) acetylation determined in tuberculosis patients treated at the Institute of Tuberculosis and Lung Diseases in Warsaw during the years 1990-1997].
    Augustynowicz-Kopeć E; Zwolska Z
    Pneumonol Alergol Pol; 2002; 70(3-4):180-92. PubMed ID: 12271965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.